Yingsi Yang

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic <i>KRAS</i> Mutant Colorectal Adenocarcinoma

J. Randolph Hecht, Al B. Benson, Dmitry Vyushkov et al. · The Oncologist · 2017 · 126 citations · Full text

Medicine, Oncology, Pharmacology +13

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2021 · 76 citations

Medicine, Oncology, Pharmacology +17

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.

Thierry André, Elena Élez, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2024 · 62 citations

Medicine, Oncology, Pharmacology +15

Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma

Kimmie Ng, Andrew Hendifar, Alexander Starodub et al. · Investigational New Drugs · 2018 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17

FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).

Daniel V.T. Catenacci, Yoon‐Koo Kang, Anwaar Saeed et al. · Journal of Clinical Oncology · 2021 · 36 citations

Medicine, Oncology, Cancer Pharmacology +9